met

Junshi Biosciences Announces Primary Endpoints Met in JS001scs Phase 3 Study for the 1ST-line Treatment of NSQ-NSCLC

SHANGHAI, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…

2 weeks ago

Ryan Group of Schools Celebrates Success at Dream Dash 2025 Grand Finale: Students Competed and Met Sprinting Legend Usain Bolt in Mumbai and New Delhi

NEW DELHI and MUMBAI, India, Oct. 20, 2025 /PRNewswire/ -- Ryan Group of Schools proudly celebrated the success of the Dream…

2 months ago

Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjgrens disease

Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to…

4 months ago

OSE Immunotherapeutics met jour linformation sur les procdures en cours

OSE Immunotherapeutics provides an update on ongoing proceedings NANTES, France, July 2, 2025, 8 AM – OSE Immunotherapeutics SA (ISIN:…

5 months ago